<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440021</url>
  </required_header>
  <id_info>
    <org_study_id>069/2017</org_study_id>
    <secondary_id>N2/19/8/2</secondary_id>
    <secondary_id>DOH-27-0218-5843</secondary_id>
    <nct_id>NCT03440021</nct_id>
  </id_info>
  <brief_title>Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers</brief_title>
  <acronym>SNAP_MRI</acronym>
  <official_title>The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate changes in neural activity (BOLD signal), as
      measured using fMRI, in brain areas associated with emotional and working memory during task
      performance after single-dose administration of a novel selective alpha2c adrenoceptor
      antagonist (ORM-12741) in healthy volunteers. Further, it will be explored whether ORM-12741
      affects connectivity between brain areas in rest, as measured using fMRI, and cognitive
      performance in the sample under investigation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>High-dosage (60mg), Low-dosage (10mg), Placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ORM-12741 on BOLD signal in fMRI of the brain areas associated with emotional memory</measure>
    <time_frame>1-1.5 hours post medication intake</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ORM-12741 on BOLD signal in fMRI of the brain areas associated with working memory</measure>
    <time_frame>1-1.5 hours post medication intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of ORM-12741 on connectivity measures between brain areas as measured with BOLD signal in fMRI obtained in a resting state</measure>
    <time_frame>1.5-2 hours post medication intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ORM-12741 on memory task performance (as measured by accuracy and response latency)</measure>
    <time_frame>1-3 hours post medication intake</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>High-dosage (60mg) ORM-12741</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 x 10 mg ORM-12741 immediate release capsules in a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dosage (10mg) ORM-12741</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 x placebo capsules in a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>Novel selective alpha2c adrenoceptor antagonist</description>
    <arm_group_label>High-dosage (60mg) ORM-12741</arm_group_label>
    <arm_group_label>Low-dosage (10mg) ORM-12741</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical in appearance to experimental drug, not psycho-active</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good command of English language

          -  right handedness

          -  normal or corrected-to-normal vision

        Exclusion Criteria:

          -  personal history or active presence of psychiatric conditions

          -  usage of psychotropic medication within the past 3 months

          -  pregnancy or breast-feeding status

          -  systolic blood pressure &lt; 90 mmHg or &gt; 140 mmHg at screening visit

          -  diastolic blood pressure &lt; 50 mmHg or &gt; 90 mmHg at screening visit

          -  resting heart rate &lt; 45 beats/minute or &gt; 100 beats/minute at screening visit

          -  active presence of medical condition at physical examination

          -  history of major traumatic brain injury

          -  any other contraindication to MRI of the brain

          -  use of psychoactive substances incl. alcohol in 24 hours prior to test session
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan J. Stein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nynke A. Groenewold, PhD</last_name>
    <phone>+27 (0) 21 406 6843</phone>
    <email>nynke.groenewold@uct.ac.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCT Dept. Psychiatry &amp; Mental Health / CUBIC</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nynke A. Groenewold, PhD</last_name>
      <phone>+27 (0) 21 406 6843</phone>
      <email>nynke.groenewold@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Nicola A. Gray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Sinclair, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Prof. Dan J. Stein</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Noradrenalin Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Mood disorders</keyword>
  <keyword>Behavioral Symptoms</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

